293 related articles for article (PubMed ID: 29777377)
21. Pharmacokinetics and tumor targeting of 131I-labeled F(ab')2 fragments of the chimeric monoclonal antibody G250: preclinical and clinical pilot studies.
Brouwers A; Mulders P; Oosterwijk E; Buijs W; Corstens F; Boerman O; Oyen W
Cancer Biother Radiopharm; 2004 Aug; 19(4):466-77. PubMed ID: 15453961
[TBL] [Abstract][Full Text] [Related]
22. Development and preclinical studies of
Lam K; Chan C; Reilly RM
MAbs; 2017 Jan; 9(1):154-164. PubMed ID: 27813707
[TBL] [Abstract][Full Text] [Related]
23. Biokinetics of a F(ab')3 iodine-131 labeled antigen binding construct (Mab 35) directed against CEA in patients with colorectal carcinoma.
Storto G; Buchegger F; Waibel R; Kuenzi G; Offord RE; Schubiger PA; Gillet M; Delaloye AB
Cancer Biother Radiopharm; 2001 Oct; 16(5):371-9. PubMed ID: 11776754
[TBL] [Abstract][Full Text] [Related]
24. Immuno-PET Imaging and Radioimmunotherapy of 64Cu-/177Lu-Labeled Anti-EGFR Antibody in Esophageal Squamous Cell Carcinoma Model.
Song IH; Lee TS; Park YS; Lee JS; Lee BC; Moon BS; An GI; Lee HW; Kim KI; Lee YJ; Kang JH; Lim SM
J Nucl Med; 2016 Jul; 57(7):1105-11. PubMed ID: 26917708
[TBL] [Abstract][Full Text] [Related]
25. Assessment of radiolabeled stabilized F(ab')2 fragments of monoclonal antiferritin in nude mouse model.
Quadri SM; Lai J; Mohammadpour H; Vriesendorp HM; Williams JR
J Nucl Med; 1993 Dec; 34(12):2152-9. PubMed ID: 8254403
[TBL] [Abstract][Full Text] [Related]
26. Radioimmunotherapy of human pancreatic cancer xenografts in NOD-scid mice with [
Boyle AJ; Cao PJ; Cai Z; Chan C; Hedley DW; Reilly RM
Nucl Med Biol; 2020; 84-85():46-54. PubMed ID: 32062317
[TBL] [Abstract][Full Text] [Related]
27. Exploration of a F(ab')
Milenic DE; Kim YS; Baidoo KE; Wong KJ; Barkley R; Delgado J; Brechbiel MW
Cancer Biother Radiopharm; 2018 Jun; 33(5):182-193. PubMed ID: 29916748
[TBL] [Abstract][Full Text] [Related]
28. Tumor targeting properties of indium-111 labeled genetically engineered Fab' and F(ab')2 constructs of chimeric tumor necrosis treatment (chTNT)-3 antibody.
Khawli LA; Alauddin MM; Hu P; Epstein AL
Cancer Biother Radiopharm; 2003 Dec; 18(6):931-40. PubMed ID: 14969605
[TBL] [Abstract][Full Text] [Related]
29. Comparative study of intact A7 MoAb and F(ab')2 fragments for radioimmunoimaging of human colon cancer in nude mice.
Kojima S; Suzuki N; Shimura N; Kubodera A; Kubota K; Yamaguchi T; Takahashi T; Oyamada H
Nucl Med Biol; 1993 Apr; 20(3):243-8. PubMed ID: 8485482
[TBL] [Abstract][Full Text] [Related]
30. Curative Multicycle Radioimmunotherapy Monitored by Quantitative SPECT/CT-Based Theranostics, Using Bispecific Antibody Pretargeting Strategy in Colorectal Cancer.
Cheal SM; Fung EK; Patel M; Xu H; Guo HF; Zanzonico PB; Monette S; Wittrup KD; Cheung NV; Larson SM
J Nucl Med; 2017 Nov; 58(11):1735-1742. PubMed ID: 28705917
[TBL] [Abstract][Full Text] [Related]
31. Specific targeting and killing activities of anti-P-glycoprotein monoclonal antibody MRK16 directed against intrinsically multidrug-resistant human colorectal carcinoma cell lines in the nude mouse model.
Iwahashi T; Okochi E; Ariyoshi K; Watabe H; Amann E; Mori S; Tsuruo T; Ono K
Cancer Res; 1993 Nov; 53(22):5475-82. PubMed ID: 8106147
[TBL] [Abstract][Full Text] [Related]
32. Biodistribution and tumor localization of 111In-labeled unmodified and modified F(ab')2 fragments of human monoclonal IgM (16.88) in a nude mouse model.
Quadri SM; Siddiqui A; Klein JL; Vriesendorp HM
Nucl Med Biol; 1995 May; 22(4):413-23. PubMed ID: 7550017
[TBL] [Abstract][Full Text] [Related]
33. Delivery of therapeutic doses of radioiodine using bispecific antibody-targeted bivalent haptens.
Gautherot E; Le Doussal JM; Bouhou J; Manetti C; Martin M; Rouvier E; Barbet J
J Nucl Med; 1998 Nov; 39(11):1937-43. PubMed ID: 9829586
[TBL] [Abstract][Full Text] [Related]
34. A novel CD44v6 targeting antibody fragment with improved tumor-to-blood ratio.
Sandström K; Haylock AK; Spiegelberg D; Qvarnström F; Wester K; Nestor M
Int J Oncol; 2012 May; 40(5):1525-32. PubMed ID: 22307465
[TBL] [Abstract][Full Text] [Related]
35. Radioimmunoimaging of human breast carcinoma xenografts in nude mouse model with 111In-labeled new monoclonal antibody EBA-1 and F(ab')2 fragments.
Yemul S; Leon JA; Pozniakoff T; Esser PD; Estabrook A
Nucl Med Biol; 1993 Apr; 20(3):325-35. PubMed ID: 8485492
[TBL] [Abstract][Full Text] [Related]
36. [Biodistribution of radiolabeled F(ab')2 fragment of monoclonal antibody Nd2 and gamma-interferon enhancement on tumor localization in nude mice with human pancreatic tumor xenografts].
Kondo Y
Nihon Geka Gakkai Zasshi; 1995 Feb; 96(2):97-105. PubMed ID: 7708049
[TBL] [Abstract][Full Text] [Related]
37. PET of hypoxia with 89Zr-labeled cG250-F(ab')2 in head and neck tumors.
Hoeben BA; Kaanders JH; Franssen GM; Troost EG; Rijken PF; Oosterwijk E; van Dongen GA; Oyen WJ; Boerman OC; Bussink J
J Nucl Med; 2010 Jul; 51(7):1076-83. PubMed ID: 20554724
[TBL] [Abstract][Full Text] [Related]
38. Tumor targeting by a multivalent single-chain Fv (scFv) anti-Lewis Y antibody construct.
Kelly MP; Lee FT; Tahtis K; Power BE; Smyth FE; Brechbiel MW; Hudson PJ; Scott AM
Cancer Biother Radiopharm; 2008 Aug; 23(4):411-23. PubMed ID: 18771345
[TBL] [Abstract][Full Text] [Related]
39. A cross-linked monoclonal antibody fragment for improved tumor targeting.
Stalteri MA; Mather SJ
Bioconjug Chem; 1995; 6(2):179-86. PubMed ID: 7599261
[TBL] [Abstract][Full Text] [Related]
40. Comparison of (99m)Tc-labeled PR81 and its F(ab')₂ fragments as radioimmunoscintigraphy agents for breast cancer imaging.
Salouti M; Babaei MH; Rajabi H; Foroutan H; Rasaee MJ; Rajabi AB; Mohammadnejad J; Shafiee M; Mazidi M; Daha FJ
Ann Nucl Med; 2011 Feb; 25(2):87-92. PubMed ID: 21061190
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
